Promising AML Data from Pharos iBio’s PHI-101 Trial
Pharos iBio’s PHI-101 shows a 50% complete response rate in AML phase 1 trial, targeting FLT3 mutation.
Pharos iBio has reported promising results from the phase 1 trial of its AML treatment, PHI-101, showing a 50% overall complete response (OCR) rate in evaluable patients. The drug targets the FLT3 gene mutation, which is linked to higher relapse rates in AML patients. The company will present these findings at the ASH 2024 conference. With support from prominent international medical institutions, Pharos iBio plans to complete the trial by the end of the year and pursue early commercialization through conditional marketing authorization.
This phase 1 trial also aims to validate PHI-101’s efficacy as a potential next-generation FLT3 inhibitor. As a key step, the company will file for an IND application for phase 2 trials to accelerate the drug’s availability for patients with rare diseases.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Curia New York recibe una carta de advertencia de la FDA por miles de inyecciones cromatográficas no documentadas
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Discussion